New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Moderna, Inc.

MRNA

Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
n/m
Free cash flow
n/m
Total debt
+13,550.0%

Quarter to September 2026, against a year earlier

195.12 4.21 −2.11%

After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.

Market cap
$79.6B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
3/9
ROIC
−35.1%
Net debt / EBITDA
1.8×
Payout ratio
—

Moderna, Inc. 10-Q filed Nov 6, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:06 PM ET · Document on sec.gov · Filing index

Red flags

  • Short cash runway

    Moderna, Inc.’s cash and short-term investments cover about 1.3 quarters of its operating cash burn

    10-Q filed · The filing · sec.gov

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Jul 31, 2026: no comparison — the earlier filing's Item cannot be compared